论文部分内容阅读
目的:研究桂枝茯苓胶囊中主要成分芍药苷、芍药内酯苷、苦杏仁苷在比格犬体内的药代动力学特征。方法:比格犬口服给予桂枝茯苓胶囊0.044 8,0.179 2 g.kg-1后,前肢静脉收集血浆样本,经固相萃取小柱富集后,HPLC-MS/MS检测血药浓度,DAS 2.0软件计算药代动力学参数。结果:芍药苷、芍药内酯苷、苦杏仁苷体内检测定量限分别为0.25,2.64,0.04μg.L-1,不同剂量下芍药苷t1/2分别为4.33,3.62 h;芍药内酯苷t1/2分别为6.16,5.91 h,苦杏仁苷t1/2分别为2.43,1.32 h;各成分体内AUC0~t与剂量有较好相关性。结论:芍药苷、芍药内酯苷、苦杏仁苷在体内均有较高暴露量,可用二室模型来描述。
Objective: To study the pharmacokinetics of paeoniflorin, paeoniflorin and amygdalin in beagle dogs. METHODS: The beagle dogs were orally administered with Guizhi Fuling capsule (0.044 8,0.179 2 g.kg-1). The plasma samples were collected from vein of forelimb. After enrichment by SPE column, the plasma concentrations of DAS 2.0 software calculates pharmacokinetic parameters. Results: The detection limits of paeoniflorin, paeoniflorin and amygdalin in vivo were 0.25, 2.64 and 0.04 μg.L-1, respectively. The paeoniflorin t1 / 2 at different doses were 4.33 and 3.62 h, respectively. / 2 respectively 6.16,5.91 h, amygdalol t1 / 2 respectively 2.43,1.32 h; AUC0 ~ t in each component has a good correlation with the dose. Conclusion: Paeoniflorin, paeoniflorin and amygdalin have higher exposure in vivo and can be described by two-compartment model.